[Disclosure] Alteogen(196170) Submits Fiscal Year Audit Report; Financial Uncertainty Resolved with ‘Unqualified’ Clean Opinions

Source Fact: Financial Supervisory Service DART / 2024-03-18

Disclosure Type: Submission of Audit Report

💡 3-Second Summary

Alteogen has officially secured ‘Unqualified’ clean audit opinions from its external auditor for both separate and consolidated financial statements, demonstrating a sharp revenue scale-up to KRW 96.5B on a consolidated basis.

📊 1. [Summary of Core Disclosure Content and Major Figures]

• Filing Entity: Alteogen Co., Ltd. (Ticker: 196170)
• External Auditor: Yichon Accounting Corporation (Report Received: March 18, 2024)
• Consolidated Financial Metrics (Based on K-IFRS):
  • Total Assets: KRW 256,099,994,583 (Increased year-on-year)
  • Total Liabilities: KRW 108,258,260,247 / Total Equity: KRW 147,841,734,336 / Capital Stock: KRW 26,505,914,000
  • Revenue: KRW 96,522,928,887 (Significantly expanded from KRW 28,806,344,498 in the prior fiscal year)
  • Operating Income: KRW -9,736,838,487 (Remaining in deficit, but loss narrowed from KRW -29.3B in the prior year)
  • Net Income: KRW -3,582,208,686 (Net loss attributable to controlling interests: KRW -3,371,764,005)
  • Audit Opinion: Unqualified (No issues regarding going concern uncertainties or material weaknesses in internal control systems)
  • Number of Consolidated Subsidiaries: 2 (Number of major subsidiaries: 1)
• Separate/Non-consolidated Financial Metrics:
  • Total Assets: KRW 203,942,847,918 / Total Liabilities: KRW 17,415,419,698 / Total Equity: KRW 186,527,428,220
  • Revenue: KRW 83,478,376,310 (Significantly expanded from KRW 8,749,918,757 in the prior fiscal year)
  • Operating Income: KRW -904,325,264 (Loss sharply reduced from KRW -21.4B in the prior year)
  • Net Income: KRW 4,870,807,532 (Turned profitable, up from KRW 2,114,427,777 in the prior year)
  • Audit Opinion: Unqualified
• Financial Health & Capital Ratios:
  • Capital Impairment Ratio: Not applicable (Total equity significantly exceeds capital stock)
  • Pre-tax Loss Ratio from Continuing Operations: 2.4% for the current fiscal year (Decreased from 6.8% in T-1 and 6.1% in T-2)
  • Impairment Loss Ratio of 50% or Higher: No

📈 2. [Expert View: What This Disclosure Means for Investors]

This regulatory filing presents the finalized, audited financial results and official audit opinions for the fiscal year. The submission of an audit report does not directly alter a biopharma company’s baseline pipeline potential; however, it serves as a critical institutional milestone by resolving accounting uncertainties and compliance risks, which fundamentally supports structural investment transparency.

The primary takeaway from this text is the confirmation of ‘unqualified’ opinions across all financial statements, eliminating any localized listing maintenance anxieties. Quantitatively, the company demonstrated notable top-line expansion, with consolidated revenue scaling to KRW 96.5B, which allowed the separate operating loss to shrink to a minor KRW 0.9B. The parent company also printed a separate net profit of KRW 4.8B. This disclosure does not explain the specific reasons for the earnings fluctuations; however, because consolidated subsidiary metrics led to a consolidated net loss of KRW 3.5B, the consolidated group has not completely exited its deficit structure. Given that the three-year pre-tax loss ratio stabilized down to 2.4% and capital impairment metrics remain entirely clear, a balanced strategy requires market participants to treat these audited books as a stable financial floor and monitor the precise timing of consolidated profitability driven by future commercial milestones.

📝 Editor’s Comment (by K-STOCK Editor)

Alteogen has successfully cleared the most critical hurdle of the March corporate season by filing its audited books. By securing clean, unqualified opinions for both consolidated and separate balance sheets from Yichon Accounting Corp., the company has entirely eliminated potential accounting concerns. Structurally, the top-line numbers are highly encouraging, with separate revenue climbing from KRW 8.7B to KRW 83.4B, and consolidated top-line tracing to KRW 96.5B. While a consolidated net loss of KRW 3.5B means a full deficit exit is still pending due to subsidiary R&D deployments, the net loss itself was compressed to roughly one-third of the previous year’s figure. Furthermore, the metrics remain perfectly safe from any regulatory warning flags like capital impairment or severe credit asset deterioration. With administrative and accounting compliance fully verified, investors would be well-advised to rely on these audited baselines to map out future cash flows from international commercial advancements.

📢 Disclaimer and Source Information

Source: This content has been structured and newly written based on the official data submitted to the Electronic Disclosure System (DART) of the Financial Supervisory Service.

Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.